Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 18/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 16/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 12/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RPS27 | P42677 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248691 | 0.89 | CYP2C9 (0.46) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4248496 | 0.84 | CYP2C9 (0.48) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4239390 | 0.83 | NAMPT (0.53) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4239542 | 0.83 | CYP2C9 (0.49) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4239914 | 0.81 | MAPK8 (0.53) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4244503 | 0.81 | MAPK8 (0.53) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL1201728 | 0.79 | NAMPT (0.42) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4241746 | 0.73 | PDE4B (0.47) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4248493 | 0.73 | CYP2C9 (0.46) | CYP2C9NAMPTMAPK8MAPK9MAPK10 | |
| SCHEMBL4239382 | 0.72 | NAMPT (0.52) | CYP2C9NAMPTMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CYP2C9 739/4885NAMPT 842/4885MAPK8 4603/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | CYP2C9 739/4885NAMPT 842/4885MAPK8 4603/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CYP2C9 739/4885NAMPT 842/4885MAPK8 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.